1. Home
  2. OCSL vs EYPT Comparison

OCSL vs EYPT Comparison

Compare OCSL & EYPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Oaktree Specialty Lending Corporation

OCSL

Oaktree Specialty Lending Corporation

HOLD

Current Price

$13.12

Market Cap

1.0B

Sector

Finance

ML Signal

HOLD

EYPT

EyePoint Pharmaceuticals Inc.

HOLD

Current Price

$14.83

Market Cap

1.1B

Sector

Industrials

ML Signal

HOLD

Company Overview

Basic Information
Metric
OCSL
EYPT
Founded
2007
1987
Country
United States
United States
Employees
N/A
N/A
Industry
Finance: Consumer Services
Biotechnology: Laboratory Analytical Instruments
Sector
Finance
Industrials
Exchange
Nasdaq
Nasdaq
Market Cap
1.0B
1.1B
IPO Year
2007
2005

Fundamental Metrics

Financial Performance
Metric
OCSL
EYPT
Price
$13.12
$14.83
Analyst Decision
Hold
Strong Buy
Analyst Count
5
5
Target Price
$13.10
$31.80
AVG Volume (30 Days)
992.9K
780.9K
Earning Date
05-05-2026
05-06-2026
Dividend Yield
12.59%
N/A
EPS Growth
N/A
N/A
EPS
0.06
N/A
Revenue
N/A
$7,539,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
$0.31
$3,115.57
P/E Ratio
$211.75
N/A
Revenue Growth
N/A
N/A
52 Week Low
$10.63
$5.44
52 Week High
$14.90
$19.11

Technical Indicators

Market Signals
Indicator
OCSL
EYPT
Relative Strength Index (RSI) 76.29 57.87
Support Level $12.50 $14.50
Resistance Level $13.89 $18.99
Average True Range (ATR) 0.30 0.65
MACD 0.19 0.26
Stochastic Oscillator 88.89 88.92

Price Performance

Historical Comparison
OCSL
EYPT

About OCSL Oaktree Specialty Lending Corporation

Oaktree Specialty Lending Corp is a specialty finance company. The company provides lending services and invests in small and mid-sized companies. The company's investment objective is to maximize its portfolio's total return by generating current income from debt investments, and to a lesser extent, capital appreciation from equity investments. The company provides customized, one-stop credit solutions to companies with limited access to public or syndicated capital markets. The company operates as a single reportable segment and derives revenues from investing in originated loans and other securities, including broadly syndicated loans, of U.S. private companies and manages the business on a consolidated basis.

About EYPT EyePoint Pharmaceuticals Inc.

EyePoint Inc focuses is a clinical-stage biopharmaceutical company committed to developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases, that may reduce the frequency of follow-up care. The company's pipeline program includes i) DURAVYU: a sustained-release product candidate for retinal diseases, with the potential to provide patients with improved visual outcomes with less burden. ii) EYP-2301: early-stage program using Durasert E technology to deliver razuprotafib, a TIE-2 agonist targeting VE-PTP for vascular stability in retinal diseases like wet AMD.

Share on Social Networks: